Pub. Date : 2018 Nov 5
PMID : 30247919
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton"s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. | ibrutinib | Bruton agammaglobulinemia tyrosine kinase | Mus musculus |
| 2 | Ibrutinib (Imbruvica), an oral tyrosine kinase inhibitor (TKI) approved for treatment of B-cell malignancies, irreversibly inhibits the Bruton"s tyrosine kinase (BTK). | ibrutinib | Bruton agammaglobulinemia tyrosine kinase | Mus musculus |
| 3 | Ibrutinib (Imbruvica), an oral tyrosine kinase inhibitor (TKI) approved for treatment of B-cell malignancies, irreversibly inhibits the Bruton"s tyrosine kinase (BTK). | ibrutinib | Bruton agammaglobulinemia tyrosine kinase | Mus musculus |
| 4 | Ibrutinib (Imbruvica), an oral tyrosine kinase inhibitor (TKI) approved for treatment of B-cell malignancies, irreversibly inhibits the Bruton"s tyrosine kinase (BTK). | ibrutinib | Bruton agammaglobulinemia tyrosine kinase | Mus musculus |
| 5 | Ibrutinib (Imbruvica), an oral tyrosine kinase inhibitor (TKI) approved for treatment of B-cell malignancies, irreversibly inhibits the Bruton"s tyrosine kinase (BTK). | ibrutinib | Bruton agammaglobulinemia tyrosine kinase | Mus musculus |
| 6 | Its abundant metabolite, dihydrodiol-ibrutinib (ibrutinib-DiOH), which is primarily formed by CYP3A, has a 10-fold reduced BTK inhibitory activity. | ibrutinib | Bruton agammaglobulinemia tyrosine kinase | Mus musculus |